Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (91-100 of 937) with videos related to

Pageof 94
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2017
Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-β and Furin in Glioma-Initiating CellsElisa Ventura, Michael Weller, Isabel Burghardt
Expert Review of Anticancer Therapy|November 18, 2010
Neuro-oncology, a decade of temozolomide and beyondRoger Stupp, Monika Hegi, Michael Weller
The Lancet. Oncology|December 3, 2014
Does cilengitide deserve another chance?-Authors' replyRoger Stupp, Martin Picard, Michael Weller
Current Opinion in Neurology|September 26, 2012
Epidermal growth factor receptor: a re-emerging target in glioblastomaMonika E Hegi, Premnath Rajakannu, Michael Weller
Cell Death Discovery|July 29, 2022
CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent mannerClara Quijano-Rubio, Manuela Silginer, Michael Weller
Journal of Cellular Physiology|August 28, 2009
Ceramide metabolism determines glioma cell resistance to chemotherapyClaudia Alexandra Dumitru, Michael Weller, Erich Gulbins
Journal of Neurochemistry|June 29, 2018
Epidermal growth factor receptor and ligand family expression and activity in glioblastomaCaroline von Achenbach, Michael Weller, Emese Szabo
Future Oncology (London, England)|March 25, 2006
Temozolomide: a milestone in the pharmacotherapy of brain tumorsMichael Weller, Joachim P Steinbach, Wolfgang Wick
Handbook of Clinical Neurology|March 8, 2016
GlioblastomaHans-Georg Wirsching, Evanthia Galanis, Michael Weller
JAMA Oncology|October 8, 2020
Appropriate Analysis of Duration of Response Data in Cancer Trials-ReplyMichael Weller, Kay Tatsuoka, David A Reardon
Pageof 94

Showing results (91-100 of 937) with videos related to

Sort By:
Pageof 94
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2017
Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-β and Furin in Glioma-Initiating CellsElisa Ventura, Michael Weller, Isabel Burghardt
Expert Review of Anticancer Therapy|November 18, 2010
Neuro-oncology, a decade of temozolomide and beyondRoger Stupp, Monika Hegi, Michael Weller
The Lancet. Oncology|December 3, 2014
Does cilengitide deserve another chance?-Authors' replyRoger Stupp, Martin Picard, Michael Weller
Current Opinion in Neurology|September 26, 2012
Epidermal growth factor receptor: a re-emerging target in glioblastomaMonika E Hegi, Premnath Rajakannu, Michael Weller
Cell Death Discovery|July 29, 2022
CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent mannerClara Quijano-Rubio, Manuela Silginer, Michael Weller
Journal of Cellular Physiology|August 28, 2009
Ceramide metabolism determines glioma cell resistance to chemotherapyClaudia Alexandra Dumitru, Michael Weller, Erich Gulbins
Journal of Neurochemistry|June 29, 2018
Epidermal growth factor receptor and ligand family expression and activity in glioblastomaCaroline von Achenbach, Michael Weller, Emese Szabo
Future Oncology (London, England)|March 25, 2006
Temozolomide: a milestone in the pharmacotherapy of brain tumorsMichael Weller, Joachim P Steinbach, Wolfgang Wick
Handbook of Clinical Neurology|March 8, 2016
GlioblastomaHans-Georg Wirsching, Evanthia Galanis, Michael Weller
JAMA Oncology|October 8, 2020
Appropriate Analysis of Duration of Response Data in Cancer Trials-ReplyMichael Weller, Kay Tatsuoka, David A Reardon
Pageof 94